Melanoma is molecularly and structurally heterogeneous, with some tumor cells existing under hypoxic conditions. Our cell growth assays showed that under controlled hypoxic conditions, BRAF(V600E) melanoma cells rapidly became resistant to vemurafenib. By employing both a three-dimensional (3D) spheroid model and a two-dimensional (2D) hypoxic culture system to model hypoxia in vivo, we identified upregulation of HGF/MET signaling as a major mechanism associated with vemurafenib resistance as compared to 2D standard tissue culture in ambient air. We further confirmed that the upregulation of HGF/MET signaling was evident in drugresistant melanoma patient tissues and mouse xenografts. Pharmacologic inhibition of the cMet/Akt pathway restored the sensitivity of melanoma spheroids or 2D hypoxic cultures to vemurafenib.
Introduction
Current research efforts have resulted in a better understanding of the genetic complexity of melanoma. Notably, somatic mutations of kinases BRAF and NRAS are present in about 60%
and 20% of melanomas (1) . A single substitution at V600E (valine to glutamate) accounts for 80% of BRAF mutations in malignant melanoma. Mutated BRAF(V600E) protein has elevated kinase activity and can promote tumor growth and resistance to apoptosis, which led to the development of the potent BRAF(V600E) inhibitor, vemurafenib (PLX4032) (2) . Multiple clinical trials of vemurafenib in metastatic melanoma patients with BRAF(V600E) mutations demonstrated a pronounced 80% antitumor response rate (3, 4) . Surprisingly, responsive patients' tumors rapidly and frequently developed resistance to vemurafenib (3, 4).
Aberrant upregulation of PDGFR-β, KIT, MET, EGFR, and MAP3K8 (the gene encoding
COT/Tpl2), and dimerization of abnormally spliced BRAF(V600E), have been observed in some PLX4032-resistant melanoma cells (5) (6) (7) (8) . These studies strongly suggest that the elevated expression of a cluster of kinases is associated with the acquired resistance to BRAF(V600E)-inhibitors in malignant melanoma. Stromal cell secretion of hepatocyte growth factor (HGF) also activates the HGF receptor, c-Met (cellular-mesenchymal to epithelial transition factor), and may contribute to PLX4032 resistance in melanoma (9) . On the basis of these data, clinical studies have been proposed to treat melanoma patients with the combination of PLX4032 with MEK or other kinase inhibitors (8, 10) . Clinical studies showed that combining mutated BRAF inhibitors (dabrafenib or vemurafenib) and the MEK inhibitors (trametinib or cobimetinib), as compared with BRAF inhibitor alone, significantly enhanced about 8% of overall survival rate in previously untreated patients with metastatic melanoma with BRAF mutations (8, 10) . However, these approaches are yet to report significant clinical outcome on preventing or delaying the onset of resistance observed with BRAF inhibitors 4 alone. It is well known that tumor heterogeneity contributes to drug resistance and tumor relapse. The structure of melanoma tumor is highly heterogeneous in vivo compared to standard two-dimensional (2D) cell cultures in CO 2 buffered ambient air. As in most solid tumors, some melanoma cells exist under hypoxia in vivo, whereas others survive in regions with increased oxygenation consistent with the normal tissue microenvironment. Numerous studies have shown that tumor hypoxia is an independent prognostic factor for disease progression (11) . Hypoxia, as defined as 1% oxygen or lower, induces a wide range of biological changes in tumors, such as increasing the expression of drug-resistance genes, selection of apoptosis-resistant clones, and metastasis (11) . However, it is still not clear whether hypoxia specifically contributes to PLX4032 resistance in melanoma. In this study, we hypothesize that melanoma cells survive under hypoxic conditions due to increased expression of uniquegrowth and survival pathways including those that alter their sensitivity to PLX4032.
To date, very few studies have addressed the effect of heterogeneous tumor threedimensional (3D) architecture on drug resistance in melanoma, particularly using an in vitro model to reproduce the heterogeneity of hypoxic regions. To test this, we employed a 3D model to grow melanoma spheroids with hypoxic centers under standard culture conditions. Based on this model, we identified the hypoxia-driven upregulation of HGF/MET signaling as one pathway responsible for attenuating PLX4032 activity in melanoma cells. We further demonstrated the trend of aberrant upregulation of HGF/MET signaling in drug-resistant melanoma patient tissues and mouse xenografts. Our studies provide valuable insights into the mechanism of vemurafenib resistance and developing more effective treatment strategies to overcome drug resistance in malignant melanoma.
Materials and Methods
Antibodies and reagents PLX4032 (vemurafenib) was purchased from Selleckchem (Houston, TX) and was dissolved in dimethyl sulfoxide (DMSO) as 100 mM stock. The c-MET specific inhibitor MSC2156119J (Tepotinib, EMD 1214063) was provided by EMD Serono (Rockland, MA) as part of a research collaboration. Structure of MSC2156119J was shown in the supplementary Figure S1 . The 4-15% gradient acrylamide gels for Western blot analyses were purchased from Bio-Rad Laboratories (Hercules, CA). Antibodies for human p53, phosphorylated p53, Akt, phosphorylated Akt (Thr308, C31E5E), and c-Met were purchased from Cell Signaling Technology (Danvers, MA). The antibody for human HIF-1α (#610958) was purchased from BD Biosciences (San Jose, CA). Antibodies for human VEGF and β-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and phosphorylated Met (pY1003, 44-882G) was purchased from Invitrogen (Life Technologies, Grand Island, NY). Neutralizing anti-HGF antibody (MAB294) was purchased from R&D Systems.
Melanoma Cell lines and 2D cultures under hypoxic and standard ambient air conditions
Human BRAF(V600E) melanoma cells, A375, were purchased from American Type Culture Collection (Manassas, VA) in 2013. Human BRAF(V600E) melanoma cells 451Lu and air, melanoma cells were grown in Dulbecco's modified Eagle medium supplemented with 5% fetal bovine serum, 100 μg/mL glutamine, 100 units/mL penicillin, and 100 units/mL streptomycin (Invitrogen). All cells were grown at 37°C in an atmosphere of 5% CO 2 and normal O 2 levels (ambient air, ~ 21% O 2 ). For 2D hypoxic cultures, melanoma cells were seeded in culture dishes and placed in a hypoxia chamber under a stable hypoxic environment of 5% CO 2 , 94% N 2 , and 1% O 2 .
3D spheroid culture and application
The inorganic nanoscale scaffolding NanoCulture Plates (NCPs) were purchased from SCIVAX (Woburn, MA). The base of each NCP is constructed with a transparent cycloolefin resinous sheet with a nanoscale indented pattern. 451Lu, A375, or MEL1617 cells were seeded in 24-well NCPs at 4×10 3 cells/well to form spheroids. The treatment of NCPs before seeding the cells and the culture conditions for the formation of melanoma spheroids were accomplished according to the manufacturer's protocols (SCIVAX). The NCPs seeded with melanoma cells were incubated in a conventional cell incubator at 37°C in an atmosphere of 5% CO 2 and normal O 2 levels. The hypoxia probe LOX-1 was also purchased from SCIVAX and dissolved in DMSO to make 1 mmol/L stock solution. The LOX-1 stock solution was diluted with RPMI medium to prepare 4 μmol/L working solution just before use. The LOX-1 working solution was added to the NCPs at a final concentration of 2 μmol/L. After culturing for one day, red phosphorescence was measured via general fluorescent microscopy (Nikon ECLIPSE TS100, G-2A filter block: Ex 510-560, DM575, BA590). On day 3 after melanoma cells being seeded on NCPs, visible spheroids started to form. The formation of spheroids was confirmed via microscopy, and all the spheroids were treated with various concentrations of PLX4032 and/or MSC2156119J as indicated in result section and figures. After drug treatment for 72 h, the cultures were subjected to MTT assay. Immunostaining of 3D cultured spheroids 7 was conducted following the standard protocol of SCIVAX. The dilution of HIF-1α antibody was 1:100.
Western blot analysis
Cells were lysed in buffer containing 50 mM Tris (pH, 7.9), 150 mM NaCl, 1% NP-40, 1 mM EDTA, 10% glycerol, 1 mM sodium vanadate, and protease inhibitor cocktail (Roche, Indianapolis, IN). Proteins were separated via electrophoresis on 4-15% gradient polyacrylamide gels with sodium dodecyl sulfate, transferred to a Hybond electrochemiluminescence (ECL) nitrocellulose membrane (GE Healthcare Biosciences, Piscataway, NJ), and blocked in 5% bovine serum albumin in PBS solution. The membrane was then incubated with primary and secondary antibodies, and target proteins were detected via ECL detection reagent (GE Healthcare Biosciences).
Human phospho-kinase array
The human phospho-kinase antibody array was purchased from R&D Systems. The protein lysates for melanoma spheroids and 2D cultures under ambient air were prepared as described in previous sections. Lysates for each sample (300 μg protein) were subjected to the human phospho-kinase array according to the manufacturer's protocol (R&D Systems). The signals of blots were developed on films, which were scanned on Kodak Image Station 4000R to determine the average signal (pixel density) of the pair of duplicate spots representing each were modelled using a nonlinear regression curve fit with a sigmoid dose-response to generate by using GraphPad Prism 6 for Windows, and the 50% inhibition point at were annotated IC 50 for drug treatments. All data were analyzed by independent-Sample t-Test.
Values between groups were compared by the Student's t-test, after ANOVA analyses. All experiments were repeated and P ≤ 0.05 was considered statistically significant.
Reverse-transcription PCR (RT-PCR) and real-time PCR analyses
The RT-PCR and real-time PCR primers used in this study are listed in supplementary Table   S1 . Total cellular RNA of melanoma cells was extracted by using a NucleoSpin RNA II kit (Macherey-Nagel, Bethlehem, PA). First-strand cDNA synthesis was performed with 500 ng of total RNA using an iScript cDNA Synthesis Kit (Bio-Rad) according to the manufacturer's protocol. A 2-μL cDNA product was used for each 20-μL RT-PCR or real-time PCR. The PCR protocol consisted of initial denaturation at 95°C for 5 min; 30 cycles of 95°C for 40 s, 55.5°C for 30 s, and 72°C for 60 s; primer extension at 72°C for 1 min; and a final extension at 72°C for 10 min. We analyzed 20 μL of PCR product on a 1.5% agarose gel. Quantitative real-time PCR was carried out using SYBR Green Mastermixes on a MasterCycler RealPlex4 (Eppendorf).
Animals and in vivo tumor experiments
Experiments were performed using adult female non-obese diabetic/severe combined immunodeficient mice (ages 6-8 weeks, Animal Production Area of the National Cancer 
Patient samples
The paraffin-embedded human melanoma tissue slides were provided by the Melanoma Core Table S2 . Tumor biopsies were performed pre-treatment (day 0) and at time of progression. Formalin-fixed tissue was analyzed to confirm that viable tumor was present via hematoxylin and eosin (H&E) staining. Additional tissue was processed for purification of RNA using the RNeasy Mini Protocol (Qiagen).
Immunohistochemical studies
We used an IHC protocol described previously (12) to detect the levels of HIF-1α, HGF, p-Met, and p-Akt. The IHC dilutions of primary antibodies were as follows: HIF-1a (1:100), HGF (1:50), p-Met (1:100), and p-Akt (Thr308) (1:100). All IHC data were manually evaluated and scored independently by 2 researchers (YQ and SE). Dr. Ekmekcioglu reviewed all IHC data as the blinded observer without prior knowledge of the staining conditions.
The Cancer Cell Line Encyclopedia (CCLE)
The Cancer Cell Line Encyclopedia (CCLE) project was developed by the Broad Institute and Novartis, which contains a detailed genetic and pharmacologic characterization of a large panel of human cancer cell lines (13) . Based on the integrated computational analyses provided by CCLE, the potential correlation between distinct pharmacologic vulnerabilities with genomic patterns in certain cell lines can be analyzed. The CCLE data used in this study are available online at the Broad Institute CCLE website (14) . In this study, we focused on analyzing data of 35 cutaneous melanoma cell lines provided by CCLE. The list of these cell lines is available in Supplementary Table S3 .
Results

Hypoxia and heterogeneity in human melanoma.
Using IHC, we consistently observed variable expression of hypoxia-inducible factor 1-alpha (HIF-1α), a well-known hypoxia marker, in some areas of A375 mouse xenografts and melanoma patient tumor samples (up to 25% noted in the tissues we assessed) ( Figure 1A ), indicating these melanoma cells are experiencing hypoxia in vivo. This data confirms that melanoma tissue is molecularly heterogeneous, and non-hypoxic and hypoxic regions co-exist within the same tumor.
BRAF(V600E) melanoma cells are resistant to PLX4032 under hypoxia.
To determine the effect of hypoxia on the efficacy of PLX4032 to inhibit melanoma cell growth, melanoma cells cultured on NCPs as early as 3 days, which was the time when spheroids started to be detected visually ( Figure 2D and supplementary Figure S4 ). This observation suggests that the formation of spheroids also drives the formation of hypoxic centers within them. After day 6 of culture, melanoma cells on NCPs formed larger spheroids, which contained larger hypoxic centers (Figure 2A and supplementary Figure S4 ). Compared to 3 days cultures, the spheroids that were cultured on NCPs for more than 5 days, expressed high levels of HIF-1α and VEGF ( Figure 2 D and E) . The expression of hypoxia-relevant genes, such as HIF-1α and VEGF, further confirms the formation of hypoxic centers within melanoma spheroids. Herein, with the NCP system, we established an in vitro 3D model to grow melanoma cells as spheroids containing hypoxic centers under standard ambient air culture conditions, a system available to most laboratories.
We further investigated the sensitivity of melanoma spheroids to PLX4032 compared to parallel 2D monolayer cultures under ambient air or hypoxia conditions. The cell viability assays showed that melanoma spheroids were 2~5 times less sensitive to PLX4032 than respective 2D ambient air cultures ( Figure 2F ). As shown in Figure 2F , 5 μM PLX4032 inhibited 20~40% of cell viability in all three melanoma cell lines cultured under hypoxia, but it inhibited about 40 ~ 50% of cell viability in the same cell spheroids. This phenomenon may be due to the fact that the melanoma cells on the surface of spheroids are not hypoxic, and are sensitive to PLX4032. Therefore, the melanoma spheroid model could be used to model a heterogeneous 3D structure with melanoma cells in a hypoxic center and surrounded by a layer of non-hypoxic melanoma cells exposed to ambient air culturing environment. Figure 4F) . Interestingly, the majority of p-Akt negative regions were also negative for p-Met and HGF ( Figure 4F ). These data suggest that p-Akt, HGF, and p-Met are upregulated in the hypoxic regions of melanoma tumor tissues. Figure 5C ). The disruption of spheroid structures is also resulted in the breakdown of hypoxic centers and the release of more melanoma cells into the standard air culture environment with higher oxygen levels, increasing sensitivity to PLX4032. Also, as shown in Figure 2F , 1 μM PLX4032 inhibited 5~15% of the growth of melanoma spheroids, suggesting that this drug concentration may be useful to evaluate the ability of cMet inhibitors to restore the sensitivity of hypoxic melanoma cells to PLX4032. To test this possibility, the combination of MSC2156119J (2 μM) and PLX4032 (1 μM) were used, and found to significantly decrease cell survival by 50 ~80% in melanoma spheroids, which is more Figure 5D ). Thus, MSC2156119J substantially potentiated the inhibitory effects of PLX4032 on the growth and formation of melanoma spheroids. We further treated melanoma 2D hypoxic cultures with PLX4032 in the presence or absence of MSC2156119J (0.5 μM). The resultant cell survival was determined via MTT assays. The IC 50 for PLX4032 alone was 9~24 μM in the 2D hypoxic cultures, which was reduced to 1~5 μM in the presence of 0.5 μM MSC2156119J (Figure 5E ), indicating a 5-to 8-fold increases of PLX4032 sensitivity in hypoxic melanoma cells. These findings confirm that blocking MET signaling potentiates the antitumor effect of PLX4032 in melanoma spheroids and 2D hypoxic cultures. Therefore, our data suggest that the combination of a cMet inhibitor and vemurafenib is a potential therapeutic strategy for overcoming hypoxia-driven PLX4032 resistance in melanoma patients.
Inhibition of c-
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High levels of HGF/MET signaling are correlated with low sensitivity to BRAF(V600E) inhibitor in melanoma cell lines.
Genetic profiles (gene expression levels and mutations) of 947 human cancer cells lines along with their sensitivity to 24 common anticancer drugs were available through the CCLE (14) .
Based on the available data in CCLE, we analyzed the sensitivity to PLX4720 in 35 human cutaneous melanoma cell lines across the gene expression patterns of HGF, MET, and VEGF-A. PLX4720 is also a potent and selective inhibitor of B-RAF(V600E). For each of the tested genes, usually there were more than 3 probes applied to measure the mRNA levels, what was considered more reliable for the predictive analysis. Unfortunately, only one probe to measure HIF-1a expression is in the CCLE data, which limits us to perform a statistical analysis to predict drug sensitivity for this gene. Since VEGF-A is a direct target of HIF-1α with 4 probes in CCLE data, we used it as an alternative hypoxia marker in our analysis of CCLE data. As shown in Figure 6A indicates that the hypoxia-driven upregulation of VEGF-A expression is correlated with increasing resistance to PLX4720 in melanoma cells. It is noted that the correlation of HGF expression levels and EC 50 of PLX4720 are statistically significant among 4 different HGF probes, and one MET probe is also statistically significant for PLX4720 EC 50 . These CCLE data confirmed that high level of HGF/MET signaling correlates with low sensitivity to BRF(V600E) inhibitor in melanoma cells.
HGF/MET signaling is upregulated in PLX4032-resistant tumor tissues from patients and mouse xenografts.
As a reasonable extension of our main hypothesis, we expected that BRAF(V600E) cells with aberrant high levels of HGF/MET signaling would be resistant to PLX4032 and that this resistance would contribute to melanoma relapse. This led to the assumption that the upregulation of HGF/MET signaling may be a phenomenon in some PLX4032-resistant melanoma cells in vivo. Therefore, we investigated the levels of HGF and p-Met in PLX4032-resistant melanoma tissues from patients and mouse xenografts. The tissues of relapsed melanoma from two A375 xenografts (G2M1 and G2M5) were compared to tumors of two A375 xenografts (G1M1 and G1M5) without PLX4032 treatment. Our IHC studies showed that the levels of HGF and p-Met in relapsed melanoma tissues were substantially higher than in the tumor samples without treatment ( Figure 6B ). Moreover, tumor biopsies were also obtained from 8 BRAF(V600E)-positive melanoma patients at pre-treatment and at time of progression on BRAF(V600E) inhibitors (patient characteristic higher in five patients than in their pre-treatment tumors ( Figure 6C ). For one patient, the HGF levels were undetectable in both pre-treatment and the progressing tumor. In two patients, HGF expression was lower in the progressing tumor than in the pre-treatment tumor. It was noted there was no specific selection for biopsies in hypoxic areas and as a result these mRNA extracts were from random tumor-rich biopsies and contained combinations of relapsed tumor and stromal cells, which may not be able to completely reflect the HGF levels within the cancer cells within hypoxic regions. Although only a small number of tumor specimens were tested in our studies, we still observed a distinct upregulation of HGF/MET signaling in 5 out of 8 BRAF(V600E)-inhibitor-resistant melanoma tumors. This data supports our contention that upregulation of HGF/MET signaling may represent a crucial drug-resistance mechanism for BRAF(V600E) inhibitors in many melanomas.
Discussion
It is known that solid tumors are structurally and molecularly heterogeneous. Tumor tissues often contain hypoxic regions, and studies have shown that tumor cells respond differently to chemotherapeutic agents in hypoxic conditions (≤ 1% O 2 ) compared to tumor cells with physiological oxygen supply (5~7% O 2 ) (18, 19) . Moreover, tumor hypoxia is significantly associated with lower overall survival and disease-free survival in several cancers (20) (21) (22) , and Figure S7) . Thus, instead of directly affecting BRAF signaling, hypoxia may modulate melanoma cells response to BRAF inhibition through other by-pass mechanisms. A previous study showed that a hypoxia-induced phenotype shift from ROR1-positive to ROR2-positive in melanoma cells leads to a 10-fold decrease in sensitivity to BRAF inhibitors (25) . Moreover, a study by Pucciarelli et al. showed that melanoma cells responded to vemurafenib under hypoxia in a cell type-specific manner, suggesting that hypoxia increases the heterogeneity of melanoma cell populations and affects the response to vemurafenib (26) . These findings indicate that hypoxic melanoma cells play a crucial role in the development of resistance to BRAF(V600E) inhibitors, and may be amenable to biologic manipulation for a more favorable therapeutic outcome. Thus, we tested whether the upregulation of HGF/MET signaling was one of hypoxia-driven mechanisms for vemurafenib resistance in melanoma, which led us to propose a new therapeutic strategy for overcoming vemurafenib resistance via the combination of a c-Met inhibitor and vemurafenib.
In the present study, we employed for the first time a 3D culture system to more closely mimic the heterogeneous mixture of hypoxic and normoxic melanoma cells in vivo. Although 2D cell cultures have been used extensively for drug development and cancer research, the limitations of standard ambient air 2D cultures (~ 21% O 2 ) are widely recognized. 3D in vitro models are now gaining popularity in cellular studies to mimic the features of an in vivo environment (27, 28) . In this study, we applied a 3D culture system to grow melanoma cells as spheroids presence or absence of anticancer drugs (29, 30) . We were able to culture uniform and reproducible melanoma spheroids based on this method, and gain novel insight into the signaling of melanoma cell growth under normally ambient air conditions but still being able to sustain a hypoxic center.
Previous studies from our laboratory and other groups showed that the upregulation of cMet/Akt signaling was associated with melanoma progression and metastatic spread (17, 31, 32) , which prompted us to investigate this pathway under hypoxia conditions and spheroids.
Our published data from both melanoma cell lines and patient samples showed that c-Met is preferentially activated in a subclass of melanoma cells without mutated BRAF that are known to be resistant to vemurafenib (17) . These findings led us to assume that the upregulation of c- 
Under hypoxic conditions, we found that many melanoma cells and melanoma tissues stained positively with p-Met [Y1003] with predominantly nuclear staining ( Figure 4D , 4F, and 6B); this observation is consistent with a previous report in non-small cell lung cancer (33) . Moreover, nuclear localization of active Met has been found not only playing a critical role in initiating calcium signaling (34) , but also correlating with an aggressive invasive/metastatic phenotype of breast carcinoma cells (35) . Our studies suggest that nuclear p-Met may have a role enhancing signaling responsible for drug resistance under hypoxic conditions. Several studies have shown that c-Met expression could be induced by hypoxia in various cancer cells due to the fact that c-Met promoter contains multiple HIF-1α binding sites (36, 37) . Moreover, previous reports showed that HIF-1α could induce HGF expression and further promote the proliferation and tube formation of endothelial progenitor cells (38) . The studies of glioma and endothelial cells revealed that hypoxia could upregulate HGF expression by stabilizing its mRNA (39) . It is known that HGF mediated signaling promotes cell proliferation and migration in a variety of cell types through activating MET/AKT signaling pathway. In lung endothelial cells, HGF induces phosphorylation of c-Met, PI3K, and Akt (T308 and S473) in a dosedependent manner (40) . Based on these studies, we propose a similar mechanism for hypoxia upregulating HGF/MET signaling and increasing activation of Akt in melanoma cells.
Under hypoxic conditions, c-Met expression is upregulated by HIF-1α, and the levels of HGF are also increased due to its stable mRNA with long half-life, which lead to increasing activation of HGF/MET signaling. Consequently, as one of major downstream targets of HGF/MET signaling, the activation of Akt is increased under hypoxia.
In our phospho-kinase arrays, we observed that the phosphorylation of Akt T308 was higher in 3D spheroids containing hypoxic centers compared to relevant 2D ambient air cultures ( Figure   3B and S5). However, there was no significant difference of phosphorylation of Akt S473 Figure 3B and S5) . It indicates that Akt phosphorylation on T398 but not on S473 correlates with hypoxia driven upregulation of HGF/MET signaling. Akt activation involves the phosphorylation of two residues, threonine 308 (T308) and serine 473 (S473). These two distinct sites can be activated independently (41) . Phosphorylation of T308 in the activation loop by PDK1 is essential for Akt activation, and phosphorylation of S473 at the C-terminal tail by either autophosphorylation or by DNA-PK is required for maximal activation of the kinase [41] . Studies in breast and lung cancer cells showed that Akt phosphorylation on T308 but not on S473 correlated with Akt kinase activity (42, 43) . Moreover, the study in lung cancer cells confirmed that Akt signaling was reactivated through a feedback-induced Akt species phosphorylated on T308 but lacking S473 (42) . The phosphorylation of Akt site is essential for downstream target specification. The most prevalent downstream targets of Akt T308 are TSC2 and GSK3 (39) . However, phosphorylation of Akt S473 selectively affects substrates FOXO1 and FOXO3a, with little effect on GSK3 and TSC2 (41) . Thus, we suspect that hypoxia mainly activates Akt T308 to upregulate its downstream TSC2 and GSK3 signaling in melanoma cells. Although our data suggests that Akt T308 is the major site responds to hypoxia signaling but not S473, further studies are needed to investigate the complex PI3K-Akt-mTOR signaling in melanoma cells under hypoxia.
Besides Akt, several markers also showed substantial differences between melanoma spheroids versus 2D ambient air cultures in our phospho-kinase arrays ( Figure 3A, supplementary Figure S5 to the hypoxic environment within the centers of spheroids, or simply caused by the unique morphology of spheroids compared to monolayer cultures. Interestingly, a recent study by Zhang et al. showed that the levels of p53 were significantly increased in response to hypoxia, resulting in reducing the stimulating effect of hypoxia on glycolysis in A549 and H460 cells (44) .
Moreover, the study by Parmenter et al. identified a network of BRAF-regulated transcription factors that control glycolysis in melanoma cells (45) . Remarkably, this network of transcription factors included HIF-1α, MYC, and MODDOA. This study showed that BRAF inhibition suppressed glycolysis via the network of transcription factors, which were critical for complete responses to BRAF inhibitor. Parmenter's group found that hypoxia could significantly increase IC 50 of vemurafenib in melanoma cells compared to normoxia (45) , which is consistent with our study. Based on these studies, similar regulatory mechanisms may occur in melanoma cells, and hypoxia-driven activation of p53 may play a critical role in antagonizing the stimulating effect of hypoxia on glycolysis, and further affects the response of cancer cells to BRAF inhibition. Further studies will be needed to resolve related mechanisms.
Although we observed a trend of HGF/MET signaling upregulation in multiple vemurafenibresistant melanoma specimens derived from patients and from mouse xenografts, we cannot conclude a significant association between HGF/MET signaling upregulation and vemurafenib resistance due to the small number of patients included in our study. However, this data now provides the rationale to prospectively and critically investigate the levels of HGF/MET signaling in a large number of melanoma patient samples. Interestingly, a reported study showed that increased plasma HGF was associated with worse outcome in BRAF-mutated metastatic melanoma patients treated with PLX4032 (46) . Although that study did not statistically confirm whether higher HGF levels confer PLX4032 resistance in patients, it suggested a clinical implication. under the same conditions. As controls, the growth of cells without drug treatment under each condition was normalized as 100% separately. Each experiment was carried out three times, and the means were presented here. Each bar denotes mean ± SD of three experiments. IC 50 values were calculated by GraphPad Prism 6. The Student's t-test was performed to compare IC 50 values of the same cell lines under different culture conditions. p ≤ 0.05 was considered statistically significant. (E) The RT-PCR analysis of VEGF expression in A375 spheroids. The induction of VEGF was observed from A375 cells cultured on NCPs for 3, 5, and 7 days, but the VEGF mRNA was undetectable in 2D ambient air cultures.
(F) The viability of 2D ambient air cultures and spheroids in three melanoma cells treated with various concentration of PLX4032. On day 4, the formation of melanoma spheroids on NCPs was confirmed by microscopy, and then they were treated with different concentrations of PLX4032. After drug treatment for 72 h, the spheroids were subjected to MTT assay. The 2D monolayer cultures of three melanoma cells under hypoxic or ambient air conditions were also subjected to PLX4032 treatment for 72 h. The Student's t-test was performed to compare cell survival at 5 μM drug concentration. p ≤ 0.05 was considered statistically significant. (A) Pearson's correlation coefficients between the expression levels of three genes (HGF, MET, and VEGF-A) and relative efficacy to PLX4720 (EC 50 ) in 35 melanoma cell lines. The red color in the heat map represents positive correlation, which indicates higher gene expression correlates with higher EC 50 of drug. For each gene, the mRNA levels were detected by multiple probes. p value of coefficient for each probe (gene expression levels) and PLX4720 EC 50 was shown at the bottom of the panel. * p ≤ 0.05.
(B) IHC staining of HGF and p-Met in melanoma tissues from A375 xenografts. G1M1 and G1M5 mice were not treated with any drug. The recurrent tumor biopsy samples were obtained from G2M1 and G2M5 mice after the initial response to PLX4032 treatment while the mice had tumor progression during treatment. 
